Oncology
Study Links Traumatic Brain Injury to Higher Brain Cancer Mortality, Urging Long-Term Monitoring
A Mass General Brigham study found that traumatic brain injury increases brain cancer mortality risk, prompting calls for revised long-term care and highlighting implications for drug developers like CNS Pharmaceuticals.
VERAXA Biotech Begins Trading on Nasdaq After Business Combination
VERAXA Biotech (VRXA) started trading on Nasdaq following a business combination with Voyager Acquisition Corp., advancing its oncology pipeline with proprietary BiTAC platform targeting solid tumors.
VERAXA Biotech Begins Trading on NASDAQ, Advances Diversified Oncology Pipeline
VERAXA Biotech AG has started trading on NASDAQ under ticker VRXA, advancing a pipeline of antibody-based cancer therapies including BiTAC platform technology aimed at improving tumor targeting and reducing toxicity.
Onco-Innovations Advances PNKP Inhibitor ONC010 as Emerging DDR Therapy
Onco-Innovations Ltd. is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor targeting DNA repair pathways, positioning itself in the DDR therapy market with AI-driven precision oncology capabilities.
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies
Aptevo Therapeutics and Niowave Inc. have formed a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, combining Aptevo's targeting platforms with Niowave's isotope supply capabilities to address a $17 billion market.
Radioactive Collagen Tiles Reduce Brain Cancer Recurrence in Clinical Trial
A clinical trial found that placing radioactive collagen tiles into the brain cavity during tumor removal dramatically cuts recurrence and extends survival, offering new hope for brain cancer treatment.
TransCode Therapeutics to Host R&D Webcast as It Advances Phase 2a Trial for Colorectal Cancer
TransCode Therapeutics will provide strategic and clinical updates during its first live R&D webcast, anchored by its Phase 2a trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer, highlighting progress in RNA-based oncology treatments.
Onco-Innovations Moves Forward with ONC010 Development and Appoints New VP of Corporate Finance
Onco-Innovations has signed a letter of intent with Nanosoft Polymers to advance its oncology candidate ONC010 and appointed Dave Antony as VP of corporate finance, signaling progress in its cancer treatment pipeline.
GeoVax Study Shows Gedeptin May Enhance Checkpoint Inhibitor Responses in Resistant Tumors
Peer-reviewed research in JCI Insight demonstrates GeoVax's Gedeptin platform can sensitize resistant tumors to immune checkpoint inhibitors and activate systemic anti-tumor immunity, potentially broadening cancer immunotherapy efficacy.
Microglia Protein Production Linked to Pediatric Brain Tumor Spread, Study Finds
Scientists discovered that microglia in the brain produce fibronectin proteins, enabling diffuse midline gliomas to spread, highlighting a potential therapeutic target for companies like CNS Pharmaceuticals.
Kairos Pharma Expands Oncology Pipeline with Proposed Acquisition of Phase 1-Ready c-MET Inhibitor
Kairos Pharma's mid-year update reveals plans to acquire CL-741, a Phase 1-ready oral c-MET inhibitor, expand clinical trials for ENV-105, and secure over $8 million in non-dilutive funding, signaling significant pipeline growth and potential advancements in cancer treatment.
Helix BioPharma Raises C$3.67M in Convertible Debenture Offering to Fund Drug Development
Helix BioPharma Corp. closed a private placement of convertible debentures raising C$3.67 million, with proceeds earmarked for working capital and advancement of its oncology drug pipeline.
New Pill Daraxonrasib Shows Promise in Doubling Survival for Pancreatic Cancer Patients
Revolution Medicines' daraxonrasib, targeting the KRAS gene, has reportedly doubled survival in early pancreatic cancer trials, offering cautious hope for a disease with limited treatment options.
Lantern Pharma Reports Phase 2 HARMONIC Trial Data Showing LP-300 Benefit in EGFR-Mutant Lung Cancer
Lantern Pharma announced updated Phase 2 data for LP-300 in EGFR L858R-mutant non-small cell lung cancer, showing improved progression-free survival and a clean safety profile, with an FDA-cleared protocol amendment extending dosing to eight cycles.
Oncotelic Therapeutics Advances Nanotech Drug Delivery Platform for Oncology and Rare Diseases
Oncotelic Therapeutics' inclusion in a BioMedWire editorial highlights the growing industry focus on advanced drug delivery technologies, with its Sapu003 program and Deciparticle platform exemplifying nanotechnology and AI-driven approaches to improve cancer therapy efficacy.
Oncotelic Therapeutics Advances Drug-Delivery Platform as Industry Focuses on Enhancing Existing Therapies
Oncotelic Therapeutics is progressing its Sapu003 program and Deciparticle platform to improve oncology drug delivery and bioavailability, aligning with industry trends favoring advanced delivery technologies over new compound development.
Onco-Innovations Advances Manufacturing Scale-Up for Lead Cancer Drug Candidate ONC010
Onco-Innovations Limited reports progress in intermediate-scale manufacturing for its nanoparticle-formulated oncology candidate ONC010, moving it closer to clinical trials in Australia.
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial evaluating TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurrence risk in a high-risk population.
Study Reveals Widespread Sexual Difficulties Among Young Cancer Survivors
A new study from Karolinska Institutet finds that sexual problems are common among young adults after cancer treatment, with severity varying by cancer type and treatment intensity.
Helix BioPharma Grants Stock Options and Cancels Previous Grant Amid Pipeline Progress
Helix BioPharma Corp. announced the grant of 1,297,000 stock options to directors, officers, employees, and consultants, while canceling 2,200,000 options previously granted to a director, as the clinical-stage oncology company advances its pipeline including L-DOS47 and other candidates.
Brain Cell Division Errors May Unlock New Cancer Treatments, Study Finds
Researchers at the University of Virginia have discovered that errors in brain cell division during development could trigger cancer and developmental disorders, offering new pathways for treatment and prevention.
UNC Researchers Develop More Targeted Immunotherapy for Acute Myeloid Leukemia
Scientists at the University of North Carolina have engineered immune cells that selectively destroy acute myeloid leukemia while sparing healthy blood tissue, potentially expanding treatment options for patients.
Lantern Pharma Gains FDA Support for HARMONIC Trial Amendments in Never-Smoker Lung Cancer
Lantern Pharma announced FDA no objections to protocol amendments for its Phase 2 HARMONIC trial of LP-300 in never-smokers with advanced NSCLC, focusing on a specific EGFR mutation subgroup.
Oncotelic Therapeutics Reports Q1 2026 Results, Highlights Progress in Oncology and AI Drug Development
Oncotelic Therapeutics reported first-quarter 2026 financial results and a corporate update, emphasizing advances in its oncology pipeline, AI-enabled drug development platform, and nose-to-brain CNS delivery system, while maintaining a $388 million valuation of its stake in GMP Biotechnology.
LIXTE Biotechnology Advances LB-100 Pipeline and Expands Proton Therapy Operations
LIXTE Biotechnology reports first-quarter progress with its lead cancer drug LB-100 moving into expanded ovarian cancer trials and growth at its Liora Technologies subsidiary, signaling strategic expansion in oncology.
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Cancer Drug Development
Lantern Pharma has closed a $4.4 million registered direct offering, providing capital to support its AI-powered oncology pipeline and commercial launch of the Zeta.ai platform.
CNS Pharmaceuticals Reports Q1 2026 Results, Advances Shift to Acquisition-Driven Growth
CNS Pharmaceuticals reported first-quarter 2026 financial results and outlined its strategic transformation toward an acquisition-driven model focused on neurology and oncology, supported by a $22.5 million private placement.
Kairos Pharma Receives 2026 Healthcare Innovation Award for Drug Resistance Research
Kairos Pharma has been recognized with the 2026 GHP Magazine Healthcare & Pharmaceutical Award as the USA leader in drug resistance development, highlighting its work on cancer therapeutics that address treatment resistance.
Testosterone Levels Linked to Glioblastoma Survival in Men, NIH-Funded Study Finds
A new NIH-funded preclinical study reveals that men with higher testosterone levels may have longer survival when diagnosed with glioblastoma, opening potential implications for treatments and companies like CNS Pharmaceuticals.
Kairos Pharma CEO to Present at LD Micro Invitational, Highlighting Clinical Progress
Kairos Pharma CEO Dr. John Yu will present at the LD Micro Invitational, providing updates on the company's clinical trials for ENV-105, a promising oncology candidate targeting drug resistance in cancer.